This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
4 Sep 2016

Dr Reddy's launches bupropion HCl extended-release tablets, USP (SR) in the US market

Therapeutic equivalent generic version of GSK's Wellbutrin SR.

Dr Reddy’s Laboratories has launched bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR (bupropion HCl) Sustained-Release Tablets in the US market approved by the FDA.

The Wellbutrin SR brand and generic had US sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016 according to IMS Health.

Dr Reddy’s Buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.

Wellbutrin SR is a registered trademark of the GSK group of companies.

Related News